Who Paid My Doc
John Karamichalis
Thoracic Surgery (Cardiothoracic Vascular Surgery) New York, NY Medical Doctor
NPI 1467651083 CMS profile 1145498
3959 Broadway, New York, NY 10032
General payments
$7,603
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, John Karamichalis of New York, NY is reported in the CMS Open Payments database as having received $7,603 across 33 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 60th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,017 | 7 | |
| 2024 | General | $624 | 4 | |
| 2023 | General | $2,072 | 8 | |
| 2022 | General | $848 | 4 | |
| 2021 | General | $632 | 6 | |
| 2020 | General | $119 | 1 | |
| 2019 | General | $2,291 | 3 |
Beside peers
- John Karamichalis
- Thoracic Surgery (Cardiothoracic Vascular Surgery) median
- Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
- National median
In program year 2025, general payments to John Karamichalis were reported at $1,017. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.
Show as a table
| Year | John Karamichalis | Thoracic Surgery (Cardiothoracic Vascular Surgery) median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,291 | $886 | $178–$3,167 | $163 |
| 2020 | $119 | $341 | $108–$1,605 | $114 |
| 2021 | $632 | $453 | $125–$1,886 | $132 |
| 2022 | $848 | $695 | $180–$2,566 | $149 |
| 2023 | $2,072 | $745 | $205–$2,662 | $160 |
| 2024 | $624 | $799 | $214–$2,967 | $164 |
| 2025 | $1,017 | $791 | $208–$3,074 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
33 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Thoracic Surgery (Cardiothoracic Vascular Surgery) in New York
Aubrey Galloway
Thoracic Surgery (Cardiothoracic Vascular Surgery) · New York, NY
Gilbert Tang
Thoracic Surgery (Cardiothoracic Vascular Surgery) · New York, NY
Michael Zervos
Thoracic Surgery (Cardiothoracic Vascular Surgery) · New York, NY
Israel Jacobowitz
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Brooklyn, NY
Elias Zias
Thoracic Surgery (Cardiothoracic Vascular Surgery) · New York, NY
Arthur Martella
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Rochester, NY
Related records
Thoracic Surgery (Cardiothoracic Vascular Surgery) in New York
Practitioners in the same specialty and state, ranked by reported value.
All Thoracic Surgery (Cardiothoracic Vascular Surgery)
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.